Skip to main content

Table 4 Distribution of births across delivery settings and coverage of uterotonics at each delivery setting in status quo and intervention scenarios. Values modelled in sensitivity analysis are indicated in parentheses

From: Cost-effectiveness of inhaled oxytocin for prevention of postpartum haemorrhage: a modelling study applied to two high burden settings

  Setting 1 Setting 2 Setting 3 Setting 4 Setting 5
Value Source Value Source Value Source Value Source Value Source
Bangladesh
Births taking place at setting 4.0% BMMS 2016 [13] 9.3% BMMS 2016 [13] 3.7% BMMS 2016 [13] 50.2% BMMS 2016 [13] 32.8% BMMS 2016 [13]
Births receiving each uterotonic in status quo
  Injectable oxytocin 90.2% Health facility survey [15] 83.9% Health facility survey [15] 11% Health facility survey [15] 0% Assumption 86% Health facility survey [15]
  Misoprostol 0% Assumption 0% Assumption 69% Health facility survey [15] Nasreen et al. 2011 [40] 42%b Quaiyum et al. 2014 [41] 0% Assumption
Births receiving each uterotonic in intervention scenarioa
  Injectable oxytocin 63% BMMS 2016 [13] 20% BMMS 2016 [13] 0% Assumption 0% Assumption 86% BMMS 2016 [13]
  Misoprostol 0% Assumption 0% Assumption 0% Assumption 0% Assumption 0% Assumption
  Inhaled oxytocin 28% Assumption 64% Assumption 80% Assumption 42% b Assumption 0% Assumption
Ethiopia
Births taking place at setting 9.5% EmONC assessment 2016 [17] 58.4% EmONC assessment 2016 [17] 4.5% Sibley et al. 2014 [18] 25.5% Sibley et al. 2014 [18] 2.1% EmONC assessment 2016 [17]
Births receiving each uterotonic in status quo
  Injectable oxytocin 81% EmONC assessment 2016 [17] 81% EmONC assessment 2016 [17] 0% Assumption 0% Assumption 81% EmONC assessment 2016 [17]
  Misoprostol 0% Assumption 0% Assumption 84%c Health facility survey [42] 0% Assumption 0% Assumption
Births receiving each uterotonic in intervention scenarioa
  Injectable oxytocin 2% EmONC assessment 2016 [17] 0% Assumption 0% Assumption 0% Assumption 81% EmONC assessment 2016 [17]
  Misoprostol 0% Assumption 0% Assumption 0% Assumption 0% Assumption 0% Assumption
  Inhaled oxytocin 78% Assumption 81% Assumption 84% c Assumption 0% Assumption 0% Assumption
  1. BMMS Bangladesh Maternal Mortality Survey, EmONC Emergency Obstetric and Neonatal Care
  2. aCoverage of uterotonics have been modelled on the basis of injectable oxytocin being used for operative deliveries, while inhaled oxytocin is used for non-operative deliveries in settings where roll-out is modelled. See appendix (Additional file 1) for estimates of operative delivery rates in each delivery setting
  3. bVaried in sensitivity analyses from 21 to 63%; (uniform distribution for probabilistic sensitivity analysis)
  4. cVaried in sensitivity analyses from 75 to 95%; (uniform distribution for probabilistic sensitivity analysis)